For the Inventor, By the Inventor

Enter assignee name

Oxfordshire, United Kingdom

Chroma Therapeutics Limited

USPTO Granted Patents = 19

% Expired Patents = 78.9

CIPO Patents = 5

EPO Patents = 13

Forward Citations = 202

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Stephen John Davies (10 out of 15 patents)

David Festus Charles Moffat (10 out of 16 patents)

Alan Hornsby Davidson (7 out of 11 patents)

4. Sanjay Ratilal Patel (6 out of 17 patents)

5. Stéphane Pintat (4 out of 6 patents)

6. Francesca Ann Mazzei (4 out of 9 patents)

7. Stuart Thomas Onions (3 out of 67 patents)

8. Alan Hastings Drummond (3 out of 7 patents)

9. Simon Christopher Hirst (3 out of 8 patents)

10. David Charles Festus Moffat (3 out of 4 patents)

11. Alistair David Graham Donald (3 out of 4 patents)

12. Kenneth William John Baker (3 out of 3 patents)

13. Tony Kouzarides (3 out of 3 patents)

14. Alastair David Graham Donald (2 out of 5 patents)

15. David Festus Moffat (2 out of 2 patents)

19 patents: Sort by Forward Citations

1. 9604940 - 2-aminopyrazine derivatives as CSF-1R kinase inhibitors (2017-03-28),

2. 9388136 - Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereof (2016-07-12),

3. 9321718 - Benzamide derivatives and their use as HSP90 inhibtors (2016-04-26),

4. 9133104 - Enzyme inhibitors (2015-09-15),

5. 8778953 - Inhibitors of P38 map kinase (2014-07-15),

6. 8686032 - Enzyme inhibitors (2014-04-01),

7. 8637547 - Compounds which inhibit members of the histone deacetylase family of enzymes and their use in the treatment of cell proliferative diseases (2014-01-28),

8. 8217050 - Adenine derivative as inhibitors of HSP90 for the treatment of cancer (2012-07-10),

9. 8211900 - DHFR enzyme inhibitors (2012-07-03),

10. 8148531 - Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity (2012-04-03),

11. 8106091 - Inhibitors of IKK-beta serine-threonine protein kinase (2012-01-31),

12. 8044211 - P38 MAP kinase inhibitors (2011-10-25),

13. 8003695 - IKK-beta serine-threonine protein kinase inhibitors (2011-08-23),

14. 7973181 - Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity (2011-07-05),

15. 7939666 - Enzyme inhibitors (2011-05-10),

Chroma Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, specializing in the development of innovative therapies for serious diseases. The organization focuses on harnessing advanced drug delivery systems and targeted therapeutics to improve patient outcomes. With a commitment to scientific excellence, Chroma Therapeutics is engaged in research that spans various therapeutic areas, aiming to address unmet medical needs through its cutting-edge technologies and collaborative partnerships within the healthcare ecosystem.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

19 Patents

#10 in Oxfordshire

#926 in United Kingdom

#32,623 in the World

Oxfordshire, United Kingdom

Chroma Therapeutics Limited

Forward Citations = 202

24 inventors:

Stephen John Davies (10 out of 15 patents)

David Festus Charles Moffat (10 out of 16 patents)

Alan Hornsby Davidson (7 out of 11 patents)

4. Sanjay Ratilal Patel (6 out of 17 patents)

5. Stéphane Pintat (4 out of 6 patents)

Please report any incorrect information to [email protected]

Loading…